Related Experiment Video
Updated: May 18, 2026
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Protein anticoagulants targeting factor VIIa-tissue factor complex: a comprehensive review
Karna Shah1, Riad Bayoumi, Yajnavalka Banerjee
1Department of Clinical Biochemistry, College of Medicine and Health Sciences, SQ University, Muscat, Oman.
Abstract:
Anticoagulants are pivotal for the treatment of debilitating thromboembolic and associated disorders. Current anticoagulants such as heparin and warfarin are non-specific and have a narrow therapeutic window. These limitations have provided the impetus to develop new anticoagulant therapies/strategies that target specific factors in the blood coagulation cascade, ideally those located upstream in the clotting process. Factor VIIa (FVIIa) presents an attractive target as it, in complex with tissue factor (TF), acts as the prima ballerina for the formation of blood clot. A comprehensive review delineating the structure-activity relationship of protein/peptide anticoagulants targeting FVIIa or TF-FVIIa complex is absent in the literature. In this article, we have addressed this deficit by appraising the peptide/protein anticoagulants that target FVIIa/TF-FVIIa complex. Further, the current status of these anticoagulants, with regard to their performance in different clinical trials has also been presented. Lastly, the unexplored domains of these unique proteins have also been highlighted, which will facilitate further translational research in this paradigm, to improve strategies to counter and treat thromboembolic disorders.
Insights
New protein and peptide anticoagulants targeting Factor VIIa (FVIIa) offer improved specificity for treating blood clots. This review details their structure-activity relationships and clinical trial performance.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- Current anticoagulants like heparin and warfarin lack specificity and have narrow therapeutic windows.
- Thromboembolic disorders necessitate the development of targeted anticoagulant therapies.
- Factor VIIa (FVIIa), in complex with tissue factor (TF), is a key upstream target in the coagulation cascade.
Purpose of the Study:
- To review protein/peptide anticoagulants targeting FVIIa or the TF-FVIIa complex.
- To delineate the structure-activity relationships of these novel anticoagulants.
- To present their current status and clinical trial performance.
Main Methods:
- Comprehensive literature review of studies on FVIIa/TF-FVIIa targeting anticoagulants.
- Analysis of structure-activity relationships for peptide and protein inhibitors.
- Evaluation of clinical trial data for efficacy and safety.
Main Results:
- Identified and appraised various peptide/protein anticoagulants targeting FVIIa/TF-FVIIa.
- Detailed structure-activity relationships for these agents.
- Summarized their performance in different clinical trial phases.
Conclusions:
- Targeting FVIIa/TF-FVIIa with protein/peptide anticoagulants represents a promising strategy for treating thromboembolic disorders.
- Further research into unexplored domains of these agents can enhance translational applications.
- These targeted anticoagulants may offer improved specificity and therapeutic windows over existing treatments.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...